Document is current
Any future updates will be listed below
-
Authors
Zhang, Haijiao
Savage, Samantha
Schultz, Anna Reister https://orcid.org/0000-0001-9977-7343
Bottomly, Daniel
White, Libbey https://orcid.org/0000-0003-4409-083X
Segerdell, Erik
Wilmot, Beth https://orcid.org/0000-0003-3579-3592
McWeeney, Shannon K. https://orcid.org/0000-0001-8333-6607
Eide, Christopher A.
Nechiporuk, Tamilla
Carlos, Amy
Henson, Rachel
Lin, Chenwei
Searles, Robert
Ho, Hoang
Lam, Yee Ling
Sweat, Richard
Follit, Courtney
Jain, Vinay
Lind, Evan
Borthakur, Gautam
Garcia-Manero, Guillermo
Ravandi, Farhad
Kantarjian, Hagop M.
Cortes, Jorge
Collins, Robert https://orcid.org/0000-0003-0313-2394
Buelow, Daelynn R.
Baker, Sharyn D.
Druker, Brian J. https://orcid.org/0000-0001-8331-8206
Tyner, Jeffrey W.
- License Information
-
More Information
Article History
Received: 1 March 2018
Accepted: 21 December 2018
First Online: 16 January 2019
Competing interests
: Research support for J.W.T. is received from Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Seattle Genetics, Syros, Takeda; co-founder of Vivid Biosciences. B.J.D. potential competing interests-- Scientific Advisory Board: Aileron Therapeutics, ALLCRON, Cepheid, Gilead Sciences, Vivid Biosciences, Celgene & Baxalta (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, GRAIL, Third Coast Therapeutics, CTI BioPharma (inactive); Scientific Founder & Stock: MolecularMD; Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license) H.H., Y.L.L., R.S., C.F. and V.J. are employees of AROG Pharmaceuticals. The remaining authors declare no competing interests.
